TopiVert Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:TopiVert Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013473
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
TopiVert Ltd (TopiVert) is a drug development company that offers disease control solutions in inflammatory diseases of the gastrointestinal tract and the eye. The company develops and offers narrow spectrum kinase inhibitors (NSKI) for the treatment of chronic inflammatory diseases of gastrointestinal and eye. It develops various drug candidates which include TOP1288 which is intended for the treatment of ulcerative colitis, a chronic, relapsing inflammatory condition. The company also offers TOP1630, a candidate used in treatment of dry eye diseases. TopiVert is headquartered in London, the UK.

TopiVert Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
TopiVert Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
TopiVert Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
TopiVert Raises USD28 Million in Venture Financing 10
TopiVert Raises US$7.4 Million In Venture Financing 12
Topivert Raises US$12.5 Million In Venture Financing 14
Partnerships 15
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 15
Licensing Agreements 16
Topivert Enters into Licensing Agreement with RespiVert 16
TopiVert Ltd – Key Competitors 17
TopiVert Ltd – Key Employees 18
TopiVert Ltd – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Clinical Trials 20
May 16, 2016: TopiVert completes preclinical development with TOP1630 for dry eye disease 20
May 09, 2016: TopiVert to Present First in Human Data From Its Phase I Clinical Study With TOP1288 at DDW 2016 in San Diego 21
Mar 17, 2016: TopiVert Reports Successful Phase I Study With TOP1288 for the Treatment Of Ulcerative Colitis 22
Mar 07, 2016: TopiVert to Present First-In-Human Data From Its Phase I Clinical Study With TOP1288 for the Treatment of Ulcerative Colitis at the Forthcoming 11th Congress of ECCO in Amsterdam 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
TopiVert Ltd, Pharmaceuticals & Healthcare, Key Facts 2
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
TopiVert Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
TopiVert Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
TopiVert Raises USD28 Million in Venture Financing 10
TopiVert Raises US$7.4 Million In Venture Financing 12
Topivert Raises US$12.5 Million In Venture Financing 14
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 15
Topivert Enters into Licensing Agreement with RespiVert 16
TopiVert Ltd, Key Competitors 17
TopiVert Ltd, Key Employees 18

★海外企業調査レポート[TopiVert Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Public Financial Holdings Ltd (626):企業の財務・戦略的SWOT分析
    Public Financial Holdings Ltd (626) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • GS Yuasa Corporation (6674):企業の財務・戦略的SWOT分析
    GS Yuasa Corporation (6674) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Panhandle Oil and Gas Inc Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    Panhandle Oil and Gas Inc Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary Panhandle Oil and Gas Inc (Panhandle) sells oil, natural gas liquid (NGL) and natural gas produced from non-operated assets through working interests, royalty interests and both in producing oi …
  • CollPlant Ltd:医療機器:M&Aディール及び事業提携情報
    Summary CollPlant Ltd (CollPlant) is a regenerative medicine company that develops and commercializes tissue repair products. The company’s product categories include orthobiologics, wound care, and pipeline products. Its orthobiologics products comprise VergenixSTR and VergenixBVF. CollPlant’s woun …
  • Energias de Portugal SA (EDP)-エネルギー分野:企業M&A・提携分析
    Summary Energias de Portugal, S.A. (EDP) is a vertically integrated power and gas utility that generates, transmits, distributes and sells electricity; and transports, distributes and sells natural gas. It produces electricity through a diversified portfolio of generation assets including wind, sola …
  • Vedanta Resources Ltd:企業の戦略的SWOT分析
    Vedanta Resources Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • American Shared Hospital Services (AMS):企業の財務・戦略的SWOT分析
    Summary American Shared Hospital Services (ASHS) is a healthcare company that offers medical equipment to hospitals and medical centers. The company offers financial and healthcare tech solutions. Its financing solutions comprise feasibility studies and reimbursement analysis, facilities planning an …
  • Srei Infrastructure Finance Ltd:企業の戦略・SWOT・財務分析
    Srei Infrastructure Finance Ltd - Strategy, SWOT and Corporate Finance Report Summary Srei Infrastructure Finance Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Altos Hornos de Mexico SAB de CV:企業の戦略・SWOT・財務情報
    Altos Hornos de Mexico SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Altos Hornos de Mexico SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • McKesson Corp (MCK)-医療機器分野:企業M&A・提携分析
    Summary McKesson Corp (McKesson) is a provider of healthcare services and information technology solutions. It distributes ethical and proprietary drugs and equipment and health and beauty care products in North America and overseas. The company also develops and provides decision support software a …
  • Semiconductor Manufacturing International Corporation:企業の戦略・SWOT・財務分析
    Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report Summary Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Prescient Therapeutics Ltd (PTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a clinical stage oncology company that develops novel drugs for the treatment of solid and hematological cancers. The company’s lead drug candidate includes PTX-200, a potent small molecule inhibitor of the …
  • Axela Inc-製薬・医療分野:企業M&A・提携分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …
  • PNM Resources, Inc. (PNM):電力:M&Aディール及び事業提携情報
    Summary PNM Resources, Inc. (PNMR) is an energy holding company. Through its utilities PNM and TNMP, the company generates, transmits, and distributes electricity; and transports natural gas. It produces electricity from coal, natural gas, nuclear, solar, wind, and geothermal sources. Through long-t …
  • AeroCentury Corp.:戦略・SWOT・企業財務分析
    AeroCentury Corp. - Strategy, SWOT and Corporate Finance Report Summary AeroCentury Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Kiewit Corp:企業の戦略的SWOT分析
    Kiewit Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Saras S.p.A. (SRS):石油・ガス:M&Aディール及び事業提携情報
    Summary Saras SpA (Saras) is crude oil refiner and operates refining, marketing, power generation and wind power businesses. The company’s major refinery is Sarroch refinery, on the Southwestern coast of Sardinia. Saras is also active in the production and sale of electricity, and offers industrial …
  • Societe Electrique de l’Our SA:企業の戦略的SWOT分析
    Societe Electrique de l'Our SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Immatics Biotechnologies GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs …
  • GENEWIZ Inc:医療機器:M&Aディール及び事業提携情報
    Summary GENEWIZ Inc (GENEWIZ) is a provider of genomics and technical support services. The company’s services comprise next generation sequencing, sanger sequencing, gene synthesis, molecular genetics, cloning and mutagenesis, plasmid DNA preparation, oligo synthesis services and GLP-compliant serv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆